News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
427,084 Results
Type
Article (35504)
Company Profile (78)
Press Release (391502)
Multimedia
Podcasts (122)
Webinars (12)
Section
Business (118584)
Career Advice (1224)
Deals (19879)
Drug Delivery (99)
Drug Development (53010)
Employer Resources (163)
FDA (12987)
Job Trends (10343)
News (209367)
Policy (21614)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (4)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Biotech Bay Standard (5)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (2)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (3)
2024 Pharm Country Standard (3)
2025 Lone Star Bio Digital (3)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (2033)
Academic (1)
Accelerated approval (5)
Adcomms (13)
Allergies (74)
Alliances (30433)
ALS (66)
Alzheimer's disease (1003)
Antibody-drug conjugate (ADC) (96)
Approvals (13006)
Artificial intelligence (212)
Autoimmune disease (16)
Automation (5)
Bankruptcy (185)
Best Places to Work (7727)
BIOSECURE Act (13)
Biosimilars (68)
Biotechnology (51)
Bladder cancer (62)
Brain cancer (22)
Breast cancer (204)
Cancer (1560)
Cardiovascular disease (147)
Career advice (1053)
Career pathing (30)
CAR-T (93)
Cell therapy (267)
Cervical cancer (15)
Clinical research (44242)
Collaboration (536)
Compensation (159)
Complete response letters (13)
COVID-19 (1842)
CRISPR (23)
C-suite (171)
Cystic fibrosis (64)
Data (1567)
Decentralized trials (2)
Denatured (44)
Depression (42)
Diabetes (200)
Diagnostics (4012)
Digital health (12)
Diversity (9)
Diversity, equity & inclusion (44)
Drug discovery (84)
Drug pricing (81)
Drug shortages (31)
Duchenne muscular dystrophy (74)
Earnings (40454)
Editorial (39)
Employer branding (23)
Employer resources (137)
Events (57350)
Executive appointments (527)
FDA (13970)
Featured Employer (17)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (4)
Funding (490)
Gene editing (61)
Generative AI (20)
Gene therapy (214)
GLP-1 (594)
Government (3485)
Grass and pollen (3)
Guidances (36)
Healthcare (13479)
Huntington's disease (14)
IgA nephropathy (23)
Immunology and inflammation (82)
Indications (21)
Infectious disease (1938)
Inflammatory bowel disease (93)
Inflation Reduction Act (10)
Influenza (26)
Intellectual property (56)
Interviews (178)
IPO (7934)
IRA (35)
Job creations (2868)
Job search strategy (920)
Kidney cancer (8)
Labor market (38)
Layoffs (330)
Leadership (13)
Legal (4202)
Liver cancer (61)
Lung cancer (250)
Lymphoma (99)
Machine learning (4)
Management (46)
Manufacturing (188)
MASH (57)
Medical device (13184)
Medtech (13187)
Mergers & acquisitions (12258)
Metabolic disorders (567)
Multiple sclerosis (61)
NASH (18)
Neurodegenerative disease (76)
Neuropsychiatric disorders (21)
Neuroscience (1403)
NextGen: Class of 2025 (4765)
Non-profit (3171)
Northern California (1471)
Now hiring (38)
Obesity (308)
Opinion (179)
Ovarian cancer (54)
Pain (71)
Pancreatic cancer (57)
Parkinson's disease (106)
Partnered (19)
Patents (134)
Patient recruitment (78)
Peanut (38)
People (38978)
Pharmaceutical (19)
Pharmacy benefit managers (13)
Phase I (12752)
Phase II (19163)
Phase III (16056)
Pipeline (793)
Policy (116)
Postmarket research (1772)
Preclinical (4232)
Press Release (40)
Prostate cancer (79)
Psychedelics (30)
Radiopharmaceuticals (184)
Rare diseases (266)
Real estate (4349)
Recruiting (60)
Regulatory (15529)
Reports (52)
Research institute (1839)
Resumes & cover letters (186)
Rett syndrome (2)
RNA editing (2)
RSV (30)
Schizophrenia (60)
Series A (97)
Series B (59)
Service/supplier (6)
Sickle cell disease (32)
Southern California (1241)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (23)
Startups (2656)
State (1)
Stomach cancer (9)
Supply chain (50)
Tariffs (19)
The Weekly (76)
United States (13774)
Vaccines (483)
Venture capitalists (32)
Weight loss (233)
Women's health (28)
Worklife (17)
Date
Today (62)
Last 7 days (271)
Last 30 days (1495)
Last 365 days (21453)
2025 (6109)
2024 (22956)
2023 (25968)
2022 (34780)
2021 (37230)
2020 (35960)
2019 (31922)
2018 (24442)
2017 (21747)
2016 (21035)
2015 (24303)
2014 (18141)
2013 (14440)
2012 (15571)
2011 (16024)
2010 (14270)
Location
Africa (568)
Alabama (20)
Alaska (2)
Arizona (122)
Arkansas (11)
Asia (26702)
Australia (4363)
California (3305)
Canada (1274)
China (402)
Colorado (168)
Connecticut (184)
Delaware (112)
Europe (56526)
Florida (575)
Georgia (142)
Idaho (38)
Illinois (381)
India (17)
Indiana (243)
Iowa (8)
Japan (120)
Kansas (78)
Kentucky (15)
Louisiana (9)
Maine (28)
Maryland (665)
Massachusetts (2393)
Michigan (152)
Minnesota (276)
Mississippi (2)
Missouri (52)
Montana (20)
Nebraska (20)
Nevada (34)
New Hampshire (62)
New Jersey (1174)
New Mexico (19)
New York (1017)
North Carolina (614)
North Dakota (4)
Northern California (1471)
Ohio (136)
Oklahoma (5)
Oregon (30)
Pennsylvania (859)
Puerto Rico (7)
Rhode Island (25)
South America (774)
South Carolina (18)
South Dakota (1)
Southern California (1241)
Tennessee (79)
Texas (557)
Utah (121)
Virginia (92)
Washington D.C. (41)
Washington State (250)
West Virginia (3)
Wisconsin (40)
427,084 Results for "ngc medical spa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Legal
Lilly’s Fight to Stop Zepbound Knockoffs Leads to Lawsuit Against Indianapolis Spa
Eli Lilly says Indianapolis-based Premier Weight Loss is cracking open auto-injector pens containing its blockbuster drug and repackaging them into separate doses.
April 7, 2025
·
4 min read
·
Annalee Armstrong
Press Releases
Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri
August 19, 2024
·
4 min read
Drug Development
Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial
Processa Pharmaceuticals, Inc. presented two abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2024, including new Phase 1b data on its Next Generation Capecitabine (NGC-Cap) product.
April 11, 2024
·
7 min read
Drug Development
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
Processa Pharmaceuticals, Inc. announces it plans to expand the development of Next Generation Capecitabine (“NGC-Cap”) into the treatment of advanced or metastatic breast cancer beginning with its next Phase 2 trial.
January 19, 2024
·
5 min read
Drug Development
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer
October 2, 2024
·
3 min read
Press Releases
Haemonetics Completes Sale of Whole Blood Assets to GVS, S.p.A
January 14, 2025
·
4 min read
Press Releases
Bioxytran Secures $1.6 million SPA to Extinguish Note & Fund Clinical Development
January 23, 2025
·
4 min read
Drug Development
Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses
Processa Pharmaceuticals, Inc. announces the successful completion of the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine (“NGC-Cap”). From the Phase 1b data, two dosage regimens have been selected for the Phase 2 trial.
January 25, 2024
·
8 min read
Press Releases
Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer
July 30, 2024
·
4 min read
Press Releases
Haemonetics Announces Sale of Whole Blood Assets to GVS, S.p.A
December 3, 2024
·
5 min read
1 of 42,709
Next
